肠道菌群对结直肠癌ICB治疗的影响
Influence of Intestinal Flora on ICB Therapy for Colorectal Cancer
DOI: 10.12677/acm.2024.14123181, PDF,   
作者: 赵 飞*:邯郸市中心医院普外二科,河北 邯郸;李爱静*:任丘市人民医院妇科,河北 任丘;夏雯晴, 张 翼, 高翔鹏#:河北医科大学研究生学院,河北 石家庄
关键词: 结直肠癌肠道菌群ICB治疗益生菌综述Colorectal Cancer Intestinal Flora ICB Therapy Probiotics Review
摘要: 肠道菌群对结直肠癌免疫检查点抑制剂(ICB)治疗的作用日益受到重视,调节肠道菌群成为了优化ICB治疗效果的一个重要研究方向,目前还缺乏既往有关肠道菌群对结直肠癌ICB治疗的研究成果的整合,并且也没有统一的临床治疗指南。本文系统、全面地探讨了肠道菌群对结直肠癌ICB治疗的影响,包括治疗机制、面临的挑战、肠道菌群与ICB治疗效果的关联、影响ICB治疗效果的肠道菌群特征等内容,并通过梳理相关文献进行了总结。本文研究表明肠道菌群在维持人体健康和疾病进程中扮演着关键角色,肠道菌群的不同组成能够显著影响ICB的治疗效果,通过粪便微生物移植、抗生素的合理使用、益生菌补充等方法调节肠道菌群成为了优化结直肠癌ICB治疗效果的一个重要研究方向。本文能够为临床制定肠道菌群干预结直肠癌ICB治疗提供一定的参考,并为更深入地探讨肠道菌群与ICB治疗之间的相互作用机制提供借鉴。
Abstract: The role of the gut microbiome in immunotherapy for colorectal cancer, particularly with immune checkpoint inhibitors (ICB), is increasingly being recognized. Modulating the gut microbiome has become an important area of research for optimizing the effects of ICB therapy. Currently, there is a lack of comprehensive integration of research findings on the gut microbiome’s impact on colorectal cancer ICB treatment, as well as a lack of unified clinical treatment guidelines. This article systematically and comprehensively explores the influence of the gut microbiome on colorectal cancer ICB treatment, including the mechanisms of therapy, challenges faced, the association between the gut microbiome and ICB treatment outcomes, and the characteristics of the gut microbiome that affect ICB treatment efficacy, summarized through a review of relevant literature. The study indicates that the gut microbiome plays a key role in maintaining human health and the disease process, with different compositions of the gut microbiome significantly impacting the efficacy of ICB treatment. Methods such as fecal microbiota transplantation, rational use of antibiotics, and probiotic supplementation to modulate the gut microbiome have become important research directions for optimizing colorectal cancer ICB treatment outcomes. This article provides references for the clinical development of gut microbiome interventions in colorectal cancer ICB treatment and offers insights for further exploration of the interaction mechanisms between the gut microbiome and ICB therapy.
文章引用:赵飞, 李爱静, 夏雯晴, 张翼, 高翔鹏. 肠道菌群对结直肠癌ICB治疗的影响[J]. 临床医学进展, 2024, 14(12): 1024-1035. https://doi.org/10.12677/acm.2024.14123181

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Siegel, R.L., Miller, K.D., Fuchs, H.E. and Jemal, A. (2022) Cancer Statistics, 2022. CA: A Cancer Journal for Clinicians, 72, 7-33. [Google Scholar] [CrossRef] [PubMed]
[3] Wang, Z., Dan, W., Zhang, N., Fang, J. and Yang, Y. (2023) Colorectal Cancer and Gut Microbiota Studies in China. Gut Microbes, 15, Article 2236364. [Google Scholar] [CrossRef] [PubMed]
[4] Tilg, H., Adolph, T.E., Gerner, R.R. and Moschen, A.R. (2018) The Intestinal Microbiota in Colorectal Cancer. Cancer Cell, 33, 954-964. [Google Scholar] [CrossRef] [PubMed]
[5] Cheng, Y., Ling, Z. and Li, L. (2020) The Intestinal Microbiota and Colorectal Cancer. Frontiers in Immunology, 11, Article 615056. [Google Scholar] [CrossRef] [PubMed]
[6] Abbott, M. and Ustoyev, Y. (2019) Cancer and the Immune System: The History and Background of Immunotherapy. Seminars in Oncology Nursing, 35, Article 150923. [Google Scholar] [CrossRef] [PubMed]
[7] Christofi, T., Baritaki, S., Falzone, L., Libra, M. and Zaravinos, A. (2019) Current Perspectives in Cancer Immunotherapy. Cancers, 11, Article 1472. [Google Scholar] [CrossRef] [PubMed]
[8] Gupta, S.L., Basu, S., Soni, V. and Jaiswal, R.K. (2022) Immunotherapy: An Alternative Promising Therapeutic Approach against Cancers. Molecular Biology Reports, 49, 9903-9913. [Google Scholar] [CrossRef] [PubMed]
[9] Kennedy, L.B. and Salama, A.K.S. (2020) A Review of Cancer Immunotherapy Toxicity. CA: A Cancer Journal for Clinicians, 70, 86-104. [Google Scholar] [CrossRef] [PubMed]
[10] Vaishnava, S., Behrendt, C.L., Ismail, A.S., Eckmann, L. and Hooper, L.V. (2008) Paneth Cells Directly Sense Gut Commensals and Maintain Homeostasis at the Intestinal Host-Microbial Interface. Proceedings of the National Academy of Sciences, 105, 20858-20863. [Google Scholar] [CrossRef] [PubMed]
[11] Belkaid, Y. and Naik, S. (2013) Compartmentalized and Systemic Control of Tissue Immunity by Commensals. Nature Immunology, 14, 646-653. [Google Scholar] [CrossRef] [PubMed]
[12] Carabotti, M., Scirocco, A., Maselli, M.A., et al. (2015) The Gut-Brain Axis: Interactions between Enteric Microbiota, Central and Enteric Nervous Systems. Annals of Gastroenterology, 28, 203-209.
[13] Magnúsdóttir, S., Ravcheev, D., de Crécy-Lagard, V. and Thiele, I. (2015) Systematic Genome Assessment of B-Vitamin Biosynthesis Suggests Co-Operation among Gut Microbes. Frontiers in Genetics, 6, Article 148. [Google Scholar] [CrossRef] [PubMed]
[14] Jandhyala, S.M. (2015) Role of the Normal Gut Microbiota. World Journal of Gastroenterology, 21, 8787-8803. [Google Scholar] [CrossRef] [PubMed]
[15] Tuddenham, S. and Sears, C.L. (2015) The Intestinal Microbiome and Health. Current Opinion in Infectious Diseases, 28, 464-470. [Google Scholar] [CrossRef] [PubMed]
[16] Gao, Y., O’Hely, M., Quinn, T.P., Ponsonby, A., Harrison, L.C., Frøkiær, H., et al. (2022) Maternal Gut Microbiota during Pregnancy and the Composition of Immune Cells in Infancy. Frontiers in Immunology, 13, Article 986340. [Google Scholar] [CrossRef] [PubMed]
[17] Odamaki, T., Kato, K., Sugahara, H., Hashikura, N., Takahashi, S., Xiao, J., et al. (2016) Age-Related Changes in Gut Microbiota Composition from Newborn to Centenarian: A Cross-Sectional Study. BMC Microbiology, 16, Article No. 90. [Google Scholar] [CrossRef] [PubMed]
[18] Greenhalgh, K., Meyer, K.M., Aagaard, K.M. and Wilmes, P. (2016) The Human Gut Microbiome in Health: Establishment and Resilience of Microbiota over a Lifetime. Environmental Microbiology, 18, 2103-2116. [Google Scholar] [CrossRef] [PubMed]
[19] Feng, Q., Chen, W. and Wang, Y. (2018) Gut Microbiota: An Integral Moderator in Health and Disease. Frontiers in Microbiology, 9, Article 151. [Google Scholar] [CrossRef] [PubMed]
[20] Garrett, W.S. (2015) Cancer and the Microbiota. Science, 348, 80-86. [Google Scholar] [CrossRef] [PubMed]
[21] Deng, H.D. and Fan, X.L. (2022) The Role of Intestinal Microbiota in Tumor Occurrence, Development and Immunotherapy: A Review. Chinese Journal of Biotechnology, 38, 2105-2119.
[22] Starnes, C.O. (1992) Coley’s Toxins in Perspective. Nature, 357, 11-12. [Google Scholar] [CrossRef] [PubMed]
[23] White, M.K., Pagano, J.S. and Khalili, K. (2014) Viruses and Human Cancers: A Long Road of Discovery of Molecular Paradigms. Clinical Microbiology Reviews, 27, 463-481. [Google Scholar] [CrossRef] [PubMed]
[24] Shi, Z., Li, H., Song, W., Zhou, Z., Li, Z. and Zhang, M. (2023) Emerging Roles of the Gut Microbiota in Cancer Immunotherapy. Frontiers in Immunology, 14, Article 1139821. [Google Scholar] [CrossRef] [PubMed]
[25] Vivarelli, S., Salemi, R., Candido, S., Falzone, L., Santagati, M., Stefani, S., et al. (2019) Gut Microbiota and Cancer: From Pathogenesis to Therapy. Cancers, 11, Article 38. [Google Scholar] [CrossRef] [PubMed]
[26] Vinay, D.S., Ryan, E.P., Pawelec, G., Talib, W.H., Stagg, J., Elkord, E., et al. (2015) Immune Evasion in Cancer: Mechanistic Basis and Therapeutic Strategies. Seminars in Cancer Biology, 35, S185-S198. [Google Scholar] [CrossRef] [PubMed]
[27] Marincola, F.M., Wang, E., Herlyn, M., Seliger, B. and Ferrone, S. (2003) Tumors as Elusive Targets of T-Cell-Based Active Immunotherapy. Trends in Immunology, 24, 334-341. [Google Scholar] [CrossRef] [PubMed]
[28] Wei, G., Zhang, H., Zhao, H., Wang, J., Wu, N., Li, L., et al. (2021) Emerging Immune Checkpoints in the Tumor Microenvironment: Implications for Cancer Immunotherapy. Cancer Letters, 511, 68-76. [Google Scholar] [CrossRef] [PubMed]
[29] Barbari, C., Fontaine, T., Parajuli, P., Lamichhane, N., Jakubski, S., Lamichhane, P., et al. (2020) Immunotherapies and Combination Strategies for Immuno-Oncology. International Journal of Molecular Sciences, 21, Article 5009. [Google Scholar] [CrossRef] [PubMed]
[30] Decker, W.K., da Silva, R.F., Sanabria, M.H., Angelo, L.S., Guimarães, F., Burt, B.M., et al. (2017) Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models. Frontiers in Immunology, 8, Article 829. [Google Scholar] [CrossRef] [PubMed]
[31] Breakstone, R. (2021) Colon Cancer and Immunotherapy—Can We Go Beyond Microsatellite Instability? Translational Gastroenterology and Hepatology, 6, 12. [Google Scholar] [CrossRef] [PubMed]
[32] Saleh, K., Kordahi, M., Felefly, T. and Khalife, N. (2021) Pembrolizumab: A New Standard of Care in Metastatic Colorectal Cancer. Immunotherapy, 13, 1245-1247. [Google Scholar] [CrossRef] [PubMed]
[33] Zhang, X., Wu, T., Cai, X., Dong, J., Xia, C., Zhou, Y., et al. (2022) Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities. Frontiers in Immunology, 13, Article 795972. [Google Scholar] [CrossRef] [PubMed]
[34] Tang, Q., Chen, Y., Li, X., Long, S., Shi, Y., Yu, Y., et al. (2022) The Role of PD-1/PD-L1 and Application of Immune-Checkpoint Inhibitors in Human Cancers. Frontiers in Immunology, 13. [Google Scholar] [CrossRef] [PubMed]
[35] Syn, N.L., Teng, M.W.L., Mok, T.S.K. and Soo, R.A. (2017) De-Novo and Acquired Resistance to Immune Checkpoint Targeting. The Lancet Oncology, 18, e731-e741. [Google Scholar] [CrossRef] [PubMed]
[36] Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., et al. (2015) Pembrolizumab versus Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 372, 2521-2532. [Google Scholar] [CrossRef] [PubMed]
[37] Sanmamed, M.F. and Chen, L. (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell, 175, 313-326. [Google Scholar] [CrossRef] [PubMed]
[38] Cheng, H., Guan, X., Chen, D. and Ma, W. (2019) The Th17/Treg Cell Balance: A Gut Microbiota-Modulated Story. Microorganisms, 7, Article 583. [Google Scholar] [CrossRef] [PubMed]
[39] Lee, G.R. (2018) The Balance of Th17 versus Treg Cells in Autoimmunity. International Journal of Molecular Sciences, 19, 730. [Google Scholar] [CrossRef] [PubMed]
[40] Erturk-Hasdemir, D., Oh, S.F., Okan, N.A., Stefanetti, G., Gazzaniga, F.S., Seeberger, P.H., et al. (2019) Symbionts Exploit Complex Signaling to Educate the Immune System. Proceedings of the National Academy of Sciences, 116, 26157-26166. [Google Scholar] [CrossRef] [PubMed]
[41] Han, Y., Ling, Q., Wu, L., Wang, X., Wang, Z., Chen, J., et al. (2023) Akkermansia muciniphila Inhibits Nonalcoholic Steatohepatitis by Orchestrating Tlr2-Activated γδt17 Cell and Macrophage Polarization. Gut Microbes, 15, Article 2221485. [Google Scholar] [CrossRef] [PubMed]
[42] Nejman, D., Livyatan, I., Fuks, G., Gavert, N., Zwang, Y., Geller, L.T., et al. (2020) The Human Tumor Microbiome Is Composed of Tumor Type-Specific Intracellular Bacteria. Science, 368, 973-980. [Google Scholar] [CrossRef] [PubMed]
[43] Zitvogel, L., Daillère, R., Roberti, M.P., Routy, B. and Kroemer, G. (2017) Anticancer Effects of the Microbiome and Its Products. Nature Reviews Microbiology, 15, 465-478. [Google Scholar] [CrossRef] [PubMed]
[44] Cogdill, A.P., Gaudreau, P.O., Arora, R., Gopalakrishnan, V. and Wargo, J.A. (2018) The Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer Therapy. Trends in Immunology, 39, 900-920. [Google Scholar] [CrossRef] [PubMed]
[45] Zhang, X., Yu, D., Wu, D., Gao, X., Shao, F., Zhao, M., et al. (2023) Tissue-Resident Lachnospiraceae Family Bacteria Protect against Colorectal Carcinogenesis by Promoting Tumor Immune Surveillance. Cell Host & Microbe, 31, 418-432.e8. [Google Scholar] [CrossRef] [PubMed]
[46] Stern, C., Kasnitz, N., Kocijancic, D., Trittel, S., Riese, P., Guzman, C.A., et al. (2015) Induction of CD4+ and CD8+ Anti‐Tumor Effector T Cell Responses by Bacteria Mediated Tumor Therapy. International Journal of Cancer, 137, 2019-2028. [Google Scholar] [CrossRef] [PubMed]
[47] Shi, Y., Zheng, W., Yang, K., Harris, K.G., Ni, K., Xue, L., et al. (2020) Intratumoral Accumulation of Gut Microbiota Facilitates CD47-Based Immunotherapy via STING Signaling. Journal of Experimental Medicine, 217, e20192282. [Google Scholar] [CrossRef] [PubMed]
[48] Belcheva, A., Irrazabal, T., Robertson, S.J., Streutker, C., Maughan, H., Rubino, S., et al. (2014) Gut Microbial Metabolism Drives Transformation of Msh2-Deficient Colon Epithelial Cells. Cell, 158, 288-299. [Google Scholar] [CrossRef] [PubMed]
[49] Arpaia, N., Campbell, C., Fan, X., Dikiy, S., van der Veeken, J., de Roos, P., et al. (2013) Metabolites Produced by Commensal Bacteria Promote Peripheral Regulatory T-Cell Generation. Nature, 504, 451-455. [Google Scholar] [CrossRef] [PubMed]
[50] Li, T., Han, L., Ma, S., Lin, W., Ba, X., Yan, J., et al. (2023) Interaction of Gut Microbiota with the Tumor Microenvironment: A New Strategy for Antitumor Treatment and Traditional Chinese Medicine in Colorectal Cancer. Frontiers in Molecular Biosciences, 10, Article 1140325. [Google Scholar] [CrossRef] [PubMed]
[51] Blount, Z.D. (2015) The Natural History of Model Organisms: The Unexhausted Potential of E. coli. eLife, 4, e05826. [Google Scholar] [CrossRef] [PubMed]
[52] Croxen, M.A. and Finlay, B.B. (2009) Molecular Mechanisms of Escherichia coli Pathogenicity. Nature Reviews Microbiology, 8, 26-38. [Google Scholar] [CrossRef] [PubMed]
[53] Pleguezuelos-Manzano, C., Puschhof, J., Rosendahl Huber, A., van Hoeck, A., Wood, H.M., Nomburg, J., et al. (2020) Mutational Signature in Colorectal Cancer Caused by Genotoxic pks+ E. coli. Nature, 580, 269-273. [Google Scholar] [CrossRef] [PubMed]
[54] Bertocchi, A., Carloni, S., Ravenda, P.S., Bertalot, G., Spadoni, I., Lo Cascio, A., et al. (2021) Gut Vascular Barrier Impairment Leads to Intestinal Bacteria Dissemination and Colorectal Cancer Metastasis to Liver. Cancer Cell, 39, 708-724.e11. [Google Scholar] [CrossRef] [PubMed]
[55] Nakkarach, A., Foo, H.L., Song, A.A., Mutalib, N.E.A., Nitisinprasert, S. and Withayagiat, U. (2021) Anti-Cancer and Anti-Inflammatory Effects Elicited by Short Chain Fatty Acids Produced by Escherichia coli Isolated from Healthy Human Gut Microbiota. Microbial Cell Factories, 20, Article No. 36. [Google Scholar] [CrossRef] [PubMed]
[56] Alizadeh, S., Esmaeili, A. and Omidi, Y. (2020) Anti-Cancer Properties of Escherichia coli Nissle 1917 against HT-29 Colon Cancer Cells through Regulation of Bax/Bcl-xL and AKT/PTEN Signaling Pathways. Iranian Journal of Basic Medical Sciences, 23, 886-893. [Google Scholar] [CrossRef] [PubMed]
[57] Brennan, C.A. and Garrett, W.S. (2018) Fusobacterium nucleatum—Symbiont, Opportunist and Oncobacterium. Nature Reviews Microbiology, 17, 156-166. [Google Scholar] [CrossRef] [PubMed]
[58] Hamada, T., Zhang, X., Mima, K., Bullman, S., Sukawa, Y., Nowak, J.A., et al. (2018) Fusobacterium nucleatum in Colorectal Cancer Relates to Immune Response Differentially by Tumor Microsatellite Instability Status. Cancer Immunology Research, 6, 1327-1336. [Google Scholar] [CrossRef] [PubMed]
[59] Liu, W., Zhang, X., Xu, H., Li, S., Lau, H.C., Chen, Q., et al. (2021) Microbial Community Heterogeneity within Colorectal Neoplasia and Its Correlation with Colorectal Carcinogenesis. Gastroenterology, 160, 2395-2408. [Google Scholar] [CrossRef] [PubMed]
[60] Gao, Y., Bi, D., Xie, R., Li, M., Guo, J., Liu, H., et al. (2021) Fusobacterium nucleatum Enhances the Efficacy of PD-L1 Blockade in Colorectal Cancer. Signal Transduction and Targeted Therapy, 6, Article No. 398. [Google Scholar] [CrossRef] [PubMed]
[61] Cheng, W.T., Kantilal, H.K. and Davamani, F. (2020) The Mechanism of Bacteroides fragilis Toxin Contributes to Colon Cancer Formation. Malaysian Journal of Medical Sciences, 27, 9-21. [Google Scholar] [CrossRef] [PubMed]
[62] Snezhkina, A.V., Krasnov, G.S., Lipatova, A.V., Sadritdinova, A.F., Kardymon, O.L., Fedorova, M.S., et al. (2016) The Dysregulation of Polyamine Metabolism in Colorectal Cancer Is Associated with Overexpression of C‐Myc and C/EBPβ Rather than Enterotoxigenic Bacteroides fragilis Infection. Oxidative Medicine and Cellular Longevity, 2016, Article 2353560. [Google Scholar] [CrossRef] [PubMed]
[63] Sears, C.L., Geis, A.L. and Housseau, F. (2014) Bacteroides fragilis Subverts Mucosal Biology: From Symbiont to Colon Carcinogenesis. Journal of Clinical Investigation, 124, 4166-4172. [Google Scholar] [CrossRef] [PubMed]
[64] Dejea, C.M., Fathi, P., Craig, J.M., Boleij, A., Taddese, R., Geis, A.L., et al. (2018) Patients with Familial Adenomatous Polyposis Harbor Colonic Biofilms Containing Tumorigenic Bacteria. Science, 359, 592-597. [Google Scholar] [CrossRef] [PubMed]
[65] Shao, X., Sun, S., Zhou, Y., Wang, H., Yu, Y., Hu, T., et al. (2021) Bacteroides fragilis Restricts Colitis-Associated Cancer via Negative Regulation of the NLRP3 Axis. Cancer Letters, 523, 170-181. [Google Scholar] [CrossRef] [PubMed]
[66] Round, J.L., Lee, S.M., Li, J., Tran, G., Jabri, B., Chatila, T.A., et al. (2011) The Toll-Like Receptor 2 Pathway Establishes Colonization by a Commensal of the Human Microbiota. Science, 332, 974-977. [Google Scholar] [CrossRef] [PubMed]
[67] Derosa, L., Routy, B., Thomas, A.M., Iebba, V., Zalcman, G., Friard, S., et al. (2022) Intestinal Akkermansia Muciniphila Predicts Clinical Response to PD-1 Blockade in Patients with Advanced Non-Small-Cell Lung Cancer. Nature Medicine, 28, 315-324. [Google Scholar] [CrossRef] [PubMed]
[68] Cani, P.D., Depommier, C., Derrien, M., Everard, A. and de Vos, W.M. (2022) Akkermansia muciniphila: Paradigm for Next-Generation Beneficial Microorganisms. Nature Reviews Gastroenterology & Hepatology, 19, 625-637. [Google Scholar] [CrossRef] [PubMed]
[69] Jin, Y., Dong, H., Xia, L., Yang, Y., Zhu, Y., Shen, Y., et al. (2019) The Diversity of Gut Microbiome Is Associated with Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients with NSCLC. Journal of Thoracic Oncology, 14, 1378-1389. [Google Scholar] [CrossRef] [PubMed]
[70] Ting, N.L., Lau, H.C. and Yu, J. (2022) Cancer Pharmacomicrobiomics: Targeting Microbiota to Optimise Cancer Therapy Outcomes. Gut, 71, 1412-1425. [Google Scholar] [CrossRef] [PubMed]
[71] Yang, M., Wang, Y., Yuan, M., Tao, M., Kong, C., Li, H., et al. (2020) Antibiotic Administration Shortly before or after Immunotherapy Initiation Is Correlated with Poor Prognosis in Solid Cancer Patients: An Up-to-Date Systematic Review and Meta-Analysis. International Immunopharmacology, 88, Article 106876. [Google Scholar] [CrossRef] [PubMed]
[72] Tinsley, N., Zhou, C., Tan, G., Rack, S., Lorigan, P., Blackhall, F., et al. (2019) Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer. The Oncologist, 25, 55-63. [Google Scholar] [CrossRef] [PubMed]
[73] Teillant, A., Gandra, S., Barter, D., Morgan, D.J. and Laxminarayan, R. (2015) Potential Burden of Antibiotic Resistance on Surgery and Cancer Chemotherapy Antibiotic Prophylaxis in the USA: A Literature Review and Modelling Study. The Lancet Infectious Diseases, 15, 1429-1437. [Google Scholar] [CrossRef] [PubMed]
[74] Yuan, L., Zhang, S., Li, H., Yang, F., Mushtaq, N., Ullah, S., et al. (2018) The Influence of Gut Microbiota Dysbiosis to the Efficacy of 5-Fluorouracil Treatment on Colorectal Cancer. Biomedicine & Pharmacotherapy, 108, 184-193. [Google Scholar] [CrossRef] [PubMed]
[75] Wilson, B.E., Routy, B., Nagrial, A. and Chin, V.T. (2019) The Effect of Antibiotics on Clinical Outcomes in Immune-Checkpoint Blockade: A Systematic Review and Meta-Analysis of Observational Studies. Cancer Immunology, Immunotherapy, 69, 343-354. [Google Scholar] [CrossRef] [PubMed]
[76] Pushalkar, S., Hundeyin, M., Daley, D., Zambirinis, C.P., Kurz, E., Mishra, A., et al. (2018) The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. Cancer Discovery, 8, 403-416. [Google Scholar] [CrossRef] [PubMed]
[77] Bullman, S., Pedamallu, C.S., Sicinska, E., Clancy, T.E., Zhang, X., Cai, D., et al. (2017) Analysis of Fusobacterium Persistence and Antibiotic Response in Colorectal Cancer. Science, 358, 1443-1448. [Google Scholar] [CrossRef] [PubMed]
[78] Kabwe, M., Dashper, S., Bachrach, G. and Tucci, J. (2021) Bacteriophage Manipulation of the Microbiome Associated with Tumour Microenvironments—Can This Improve Cancer Therapeutic Response? FEMS Microbiology Reviews, 45, fuab017. [Google Scholar] [CrossRef] [PubMed]
[79] Dolgin, E. (2020) Fighting Cancer with Microbes. Nature, 577, S16-S18. [Google Scholar] [CrossRef] [PubMed]
[80] Zheng, D., Dong, X., Pan, P., Chen, K., Fan, J., Cheng, S., et al. (2019) Phage-Guided Modulation of the Gut Microbiota of Mouse Models of Colorectal Cancer Augments Their Responses to Chemotherapy. Nature Biomedical Engineering, 3, 717-728. [Google Scholar] [CrossRef] [PubMed]
[81] Zhao, T., Xie, L., Cai, S., Xu, J., Zhou, H., Tang, L., et al. (2021) Dysbiosis of Gut Microbiota Is Associated with the Progression of Radiation-Induced Intestinal Injury and Is Alleviated by Oral Compound Probiotics in Mouse Model. Frontiers in Cellular and Infection Microbiology, 11, Article 717636. [Google Scholar] [CrossRef] [PubMed]
[82] Chang, C., Liu, C., Lee, H., Huang, Y., Li, L., Chiau, J.C., et al. (2018) Lactobacillus Casei Variety Rhamnosus Probiotic Preventively Attenuates 5-Fluorouracil/Oxaliplatin-Induced Intestinal Injury in a Syngeneic Colorectal Cancer Model. Frontiers in Microbiology, 9, Article 983. [Google Scholar] [CrossRef] [PubMed]
[83] Gao, G., Shen, S., Zhang, T., Zhang, J., Huang, S., Sun, Z., et al. (2023) Lacticaseibacillus rhamnosus Probio-M9 Enhanced the Antitumor Response to Anti-PD-1 Therapy by Modulating Intestinal Metabolites. eBioMedicine, 91, Article 104533. [Google Scholar] [CrossRef] [PubMed]
[84] Shi, L., Sheng, J., Wang, M., Luo, H., Zhu, J., Zhang, B., et al. (2019) Combination Therapy of TGF-Β Blockade and Commensal-Derived Probiotics Provides Enhanced Antitumor Immune Response and Tumor Suppression. Theranostics, 9, 4115-4129. [Google Scholar] [CrossRef] [PubMed]
[85] Naito, Y., Uchiyama, K. and Takagi, T. (2018) A Next-Generation Beneficial Microbe: Akkermansia muciniphila. Journal of Clinical Biochemistry and Nutrition, 63, 33-35. [Google Scholar] [CrossRef] [PubMed]
[86] Spencer, C.N., Mcquade, J.L., Gopalakrishnan, V., McCulloch, J.A., Vetizou, M., Cogdill, A.P., et al. (2021) Dietary Fiber and Probiotics Influence the Gut Microbiome and Melanoma Immunotherapy Response. Science, 374, 1632-1640. [Google Scholar] [CrossRef] [PubMed]
[87] Borody, T.J. and Khoruts, A. (2011) Fecal Microbiota Transplantation and Emerging Applications. Nature Reviews Gastroenterology & Hepatology, 9, 88-96. [Google Scholar] [CrossRef] [PubMed]
[88] Yu, H., Li, X., Han, X., Chen, B., Zhang, X., Gao, S., et al. (2023) Fecal Microbiota Transplantation Inhibits Colorectal Cancer Progression: Reversing Intestinal Microbial Dysbiosis to Enhance Anti-Cancer Immune Responses. Frontiers in Microbiology, 14, Article 1126808. [Google Scholar] [CrossRef] [PubMed]
[89] Routy, B., Le Chatelier, E., Derosa, L., et al. (2018) Gut Microbiome Influences Efficacy of PD-1-Based Immunotherapy against Epithelial Tumors. Science (New York, N.Y.), 359, 91-97.
[90] Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M., et al. (2018) The Commensal Microbiome Is Associated with Anti-PD-1 Efficacy in Metastatic Melanoma Patients. Science, 359, 104-108. [Google Scholar] [CrossRef] [PubMed]
[91] Wang, Y., Wiesnoski, D.H., Helmink, B.A., Gopalakrishnan, V., Choi, K., DuPont, H.L., et al. (2018) Fecal Microbiota Transplantation for Refractory Immune Checkpoint Inhibitor-Associated Colitis. Nature Medicine, 24, 1804-1808. [Google Scholar] [CrossRef] [PubMed]
[92] Feuerstadt, P., Louie, T.J., Lashner, B., Wang, E.E.L., Diao, L., Bryant, J.A., et al. (2022) SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. New England Journal of Medicine, 386, 220-229. [Google Scholar] [CrossRef] [PubMed]
[93] Giles, E.M., D’Adamo, G.L. and Forster, S.C. (2019) The Future of Faecal Transplants. Nature Reviews Microbiology, 17, 719-719. [Google Scholar] [CrossRef] [PubMed]
[94] Kartal, E., Schmidt, T.S.B., Molina-Montes, E., Rodríguez-Perales, S., Wirbel, J., Maistrenko, O.M., et al. (2022) A Faecal Microbiota Signature with High Specificity for Pancreatic Cancer. Gut, 71, 1359-1372. [Google Scholar] [CrossRef] [PubMed]
[95] Yachida, S., Mizutani, S., Shiroma, H., Shiba, S., Nakajima, T., Sakamoto, T., et al. (2019) Metagenomic and Metabolomic Analyses Reveal Distinct Stage-Specific Phenotypes of the Gut Microbiota in Colorectal Cancer. Nature Medicine, 25, 968-976. [Google Scholar] [CrossRef] [PubMed]
[96] Yu, T., Guo, F., Yu, Y., Sun, T., Ma, D., Han, J., et al. (2017) Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy. Cell, 170, 548-563.e16. [Google Scholar] [CrossRef] [PubMed]
[97] Flanagan, L., Schmid, J., Ebert, M., Soucek, P., Kunicka, T., Liska, V., et al. (2014) Fusobacterium nucleatum Associates with Stages of Colorectal Neoplasia Development, Colorectal Cancer and Disease Outcome. European Journal of Clinical Microbiology & Infectious Diseases, 33, 1381-1390. [Google Scholar] [CrossRef] [PubMed]